The efficacy and safety of ombitasvir/paritaprevir/ritonavir plus ribavirin in hepatitis C virus-infected patients with end-stage renal disease on regular hemodialysis

The efficacy and safety of ombitasvir/paritaprevir/ritonavir plus ribavirin in hepatitis C virus-infected patients with end-stage renal disease on regular hemodialysis

Background and aim Infection with hepatitis C virus (HCV) is an important cause of mortality and morbidity in patients with end-stage renal disease. Direct-acting antiviral drugs allow for the treatment of this group of patients. The current research aims to assess the efficacy and safety of ombitas...

Full description

Bibliographic Details
Main Authors: Muhammad M A. Ghaffar, Dalia Omran, Enass El Sayed
Format: Article
Language:English
Published: General Organization of Teaching Hospitals and Institutes 2021-01-01
Series:Journal of Medicine in Scientific Research
Subjects:
chronic hepatitis c virus
direct-acting antiviral therapy
efficacy
hemodialysis
ombitasvir/paritaprevir/ritonavir combination therapy
safety
sustained virological response
treatment
Online Access:http://www.jmsr.eg.net/article.asp?issn=2537-091X;year=2021;volume=4;issue=2;spage=170;epage=175;aulast=A.

Internet

http://www.jmsr.eg.net/article.asp?issn=2537-091X;year=2021;volume=4;issue=2;spage=170;epage=175;aulast=A.

Similar Items